363 related articles for article (PubMed ID: 23867515)
1. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.
Ramakrishnan S; Pili R
Cancer J; 2013; 19(4):333-40. PubMed ID: 23867515
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
3. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
4. Involvement of noncoding RNAs in epigenetic modifications of esophageal cancer.
Xiao Y; Su M; Ou W; Wang H; Tian B; Ma J; Tang J; Wu J; Wu Z; Wang W; Zhou Y
Biomed Pharmacother; 2019 Sep; 117():109192. PubMed ID: 31387188
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation and cancer (review).
Chen QW; Zhu XY; Li YY; Meng ZQ
Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
[TBL] [Abstract][Full Text] [Related]
6. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
7. Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications.
Silverman BR; Shi J
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999365
[TBL] [Abstract][Full Text] [Related]
8. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
Maleszewska M; Kaminska B
Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
10. Deregulated chromatin remodeling in the pathobiology of brain tumors.
Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
[TBL] [Abstract][Full Text] [Related]
11. Histone modifications: implications in renal cell carcinoma.
Ramakrishnan S; Ellis L; Pili R
Epigenomics; 2013 Aug; 5(4):453-62. PubMed ID: 23895657
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
Bhalla KN
J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
[TBL] [Abstract][Full Text] [Related]
13. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
Valdespino-Gómez VM; Valdespino-Castillo VE
Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
[TBL] [Abstract][Full Text] [Related]
14. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
16. Chromatin remodeling and histone modifications in pituitary tumors.
Tateno T; Zhu X; Asa SL; Ezzat S
Mol Cell Endocrinol; 2010 Sep; 326(1-2):66-70. PubMed ID: 20060434
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of chromatin remodeling and DNA damage in stem cells induced by environmental and dietary agents.
Bariar B; Vestal CG; Richardson C
J Environ Pathol Toxicol Oncol; 2013; 32(4):307-27. PubMed ID: 24579784
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
Walsh L; Gallagher WM; O'Connor DP; Ní Chonghaile T
Expert Rev Mol Diagn; 2016; 16(5):541-51. PubMed ID: 26895288
[TBL] [Abstract][Full Text] [Related]
19. Epigenetics of Huntington's Disease.
Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M
Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552
[TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic alterations during renal carcinogenesis.
Arai E; Kanai Y
Int J Clin Exp Pathol; 2010 Dec; 4(1):58-73. PubMed ID: 21228928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]